Ono Pharmaceutical (4528) Earnings Miss Estimates: Operating Income and Net Income Fall Short Despite Sales Growth

Ono Pharmaceutical on Smartkarma

Analysts on Smartkarma, such as Tina Banerjee, have provided their insights on Ono Pharmaceutical (4528 JP). In a recent report titled “Ono Pharmaceutical (4528 JP): Label Expansion Helps, But Long-Term Growth Momentum Calls for More”, Banerjee highlights that Ono Pharmaceutical expects a 4% year-over-year growth in Opdivo revenue for FY26. This growth is driven by indication expansion, with a focus on Opdivo in combination with Yervoy for the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma. While the company anticipates revenue growth in the short term, concerns about a smaller patient population pose challenges for long-term growth prospects.

A look at Ono Pharmaceutical Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Ono Pharmaceutical‘s long-term outlook based on Smartkarma Smart Scores reveals a positive trajectory with strong indicators. The company scores high in Dividend and Value factors, suggesting stability and attractiveness for investors seeking consistent returns. Additionally, Ono Pharmaceutical demonstrates resilience in its operations, further solidifying its position in the pharmaceutical industry. While Growth and Momentum scores are not as high, the overall outlook remains promising for the company in the long run.

ONO PHARMACEUTICAL CO., LTD., known for manufacturing and selling pharmaceuticals with a focus on prescription drugs, presents a robust profile in terms of financial metrics. With a blend of solid dividends, value proposition, and resilience, Ono Pharmaceutical stands out as a reliable player in the pharmaceutical market. Although growth and momentum might require attention, the company’s core strengths position it well for sustained success in the future.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma